Compare Dishman Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs BIOCON - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA BIOCON DISHMAN PHARMA/
BIOCON
 
P/E (TTM) x 25.1 25.3 99.3% View Chart
P/BV x 3.3 3.3 100.0% View Chart
Dividend Yield % 0.7 0.3 192.0%  

Financials

 DISHMAN PHARMA   BIOCON
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
BIOCON
Mar-18
DISHMAN PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs3741,188 31.5%   
Low Rs129305 42.3%   
Sales per share (Unadj.) Rs197.868.7 287.8%  
Earnings per share (Unadj.) Rs21.27.6 280.8%  
Cash flow per share (Unadj.) Rs34.714.0 248.5%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.80.1 593.3%  
Book value per share (Unadj.) Rs179.986.3 208.3%  
Shares outstanding (eoy) m80.69600.00 13.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x1.310.9 11.7%   
Avg P/E ratio x11.998.9 12.0%  
P/CF ratio (eoy) x7.253.4 13.6%  
Price / Book Value ratio x1.48.6 16.2%  
Dividend payout %9.413.2 71.2%   
Avg Mkt Cap Rs m20,306447,900 4.5%   
No. of employees `0000.86.1 13.5%   
Total wages/salary Rs m5,3559,311 57.5%   
Avg. sales/employee Rs Th19,252.76,705.8 287.1%   
Avg. wages/employee Rs Th6,459.51,514.2 426.6%   
Avg. net profit/employee Rs Th2,064.1736.9 280.1%   
INCOME DATA
Net Sales Rs m15,96141,234 38.7%  
Other income Rs m2652,062 12.9%   
Total revenues Rs m16,22643,296 37.5%   
Gross profit Rs m4,1038,291 49.5%  
Depreciation Rs m1,0913,851 28.3%   
Interest Rs m944615 153.6%   
Profit before tax Rs m2,3345,887 39.6%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,569 39.7%   
Profit after tax Rs m1,7114,531 37.8%  
Gross profit margin %25.720.1 127.9%  
Effective tax rate %26.726.7 100.3%   
Net profit margin %10.711.0 97.6%  
BALANCE SHEET DATA
Current assets Rs m11,01841,486 26.6%   
Current liabilities Rs m9,51721,413 44.4%   
Net working cap to sales %9.448.7 19.3%  
Current ratio x1.21.9 59.8%  
Inventory Days Days11064 172.7%  
Debtors Days Days3594 37.0%  
Net fixed assets Rs m16,30450,661 32.2%   
Share capital Rs m1613,000 5.4%   
"Free" reserves Rs m12,90748,808 26.4%   
Net worth Rs m14,51651,808 28.0%   
Long term debt Rs m4,18917,898 23.4%   
Total assets Rs m29,80599,897 29.8%  
Interest coverage x3.510.6 32.8%   
Debt to equity ratio x0.30.3 83.5%  
Sales to assets ratio x0.50.4 129.7%   
Return on assets %8.95.2 173.0%  
Return on equity %11.88.7 134.8%  
Return on capital %17.59.6 182.0%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95212,058 41.1%   
Fx outflow Rs m6977,348 9.5%   
Net fx Rs m4,2554,710 90.3%   
CASH FLOW
From Operations Rs m2,7866,621 42.1%  
From Investments Rs m-1,529-6,840 22.4%  
From Financial Activity Rs m-941-2,397 39.3%  
Net Cashflow Rs m316-2,612 -12.1%  

Share Holding

Indian Promoters % 61.4 40.4 152.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 3.7 8.4 44.0%  
FIIs % 12.7 10.7 118.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 19.9 111.1%  
Shareholders   46,261 109,995 42.1%  
Pledged promoter(s) holding % 35.8 0.0 89,400.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS